Chemaphor Inc. operates in the multi-billion dollar animal and human health markets. The company’s goal is to commercialize a range of product applications from its technology platforms with:
- secured licensing agreements
- collaborations and alliances with selected industry partners
- the successful launch of pet products in the US and Canada
- the strengthening of an already sound IP portfolio
Chemaphor's technologies are based on Natural Health Optimizers ("NHOs"). NHOs work with and support the natural systems that exist within the body to strive to maintain optimal health and function, e,g, by supporting immune function. Chemaphor’s two major technologies are Fully Oxidized Beta-Carotene (OxC-beta) and Vet-Stem Regenerative Cells (VSRC).
Chemaphor’s target NHO markets are:
- Pet Wellness
- Human health and Wellness
- Livestock Health & Productivity Enhancement
- The OxC-beta platform addresses all three target markets, and VSRC therapy is specifically targeted towards the Pet Wellness market.
Chemaphor is a publicly listed biotechnology company trading on the TSX Venture Exchange under the ticker "CFR". The company has two R&D operations located in the Industrial Partnership Facilities in NRC’s Steacie Institute for Molecular Sciences in Ottawa (Chemistry), and the Institute for Nutrisciences and Health in Charlottetown, Prince Edward Island (Nutriscience). Chemaphor is headquartered in Ottawa, Canada and was established August 4th, 2005.
Chemaphor Inc. Head Office:
100 Sussex Drive, Ottawa, ON K1A 0R6
Tel: (613) 949-8164
The Richmond Club
Richmond Club employees may or may not own share of the companies that are showcased by the Richmond Club